Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progression

V2, Crosslink

🧫

Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progression

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-alpha-sy

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progression ## Background and Rationale Parkinson's disease (PD) clinical staging currently relies on motor symptom progression, which poorly reflects underlying biological heterogeneity and limits precision therapeutic approaches. Accumulating evidence suggests that alpha-synuclein (α-syn) pathological species exhibit distinct seeding and propagation kinetics that may define biologically meaningful disease subtypes. This

METHODOLOGY NOTES

Phase 1 (Months 0-6): Recruit 200 early PD patients (Hoehn-Yahr 1-2, <3 years since diagnosis), 100 prodromal subjects (REM sleep behavior disorder with abnormal DaTscan), and 100 age-matched healthy controls. Obtain baseline lumbar punctures for CSF collection (15mL), comprehensive clinical assessments (MDS-UPDRS, Montreal Cognitive Assessment), and DaTscan imaging. Phase 2 (Months 0-36): Perform α-syn SAA using recombinant α-syn fibrils as seeds with CSF samples in quadruplicate using thioflavin-T fluorescence monitoring every 15 minutes for 100 hours. Extract kinetic parameters: lag time (hours to 10% maximum fluorescence), growth rate (slope of exponential phase), and maximum amplitude. Simultaneously measure CSF neurofilament light, total tau, and phospho-tau181 by ultrasensitive immunoassays. Phase 3 (Months 6, 12, 24, 36): Conduct longitudinal follow-up visits with clinical assessments, repeat neuroimaging at 18 and 36 months, and optional repeat lumbar punctures at 18 and 36 mo

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.901032Z'}
summary	# Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progression ## Background and Rationale Parkinson's disease (PD) clinical staging currently relies on motor symptom progressio
entities	{'genes': ['SAA'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Development of a validated biological staging algorithm based on alpha-synuclein SAA kinetic parameters that predicts 24-month clinical progression (MDS-UPDRS Part III change) with >80% accuracy acros
methodology_notes	Phase 1 (Months 0-6): Recruit 200 early PD patients (Hoehn-Yahr 1-2, <3 years since diagnosis), 100 prodromal subjects (REM sleep behavior disorder with abnormal DaTscan), and 100 age-matched healthy
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.901036', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

655

Outgoing

630

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progression

derives from (16)

supports (5)

💬 Discussion